Q32 Bio Announces 36-Week Topline Results From Part B Of SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA

Loading news article.

Q32 Bio Announces 36-Week Topline Results From Part B Of SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA | WAPE

Q32 Bio Announces 36-Week Topline Results From Part B Of SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA

Article summary

Related companies

Comments —